RxDoctor Payments Data

Christopher Podgorski, MD

Rheumatology · Burnsville, MNNPI 1902369424

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by AbbVie at 48.9% of the total. Reporting peaked in 2023 at $427 and has fallen 71.4% since, to $122 in 2024.

$617in general payments, 2019–2025

Across 26 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$302
  • GSK$125
  • Pfizer$79
  • Johnson & Johnson$65
  • UCB, Inc.$29
  • Amgen$17

What the payments were for

  • Food & beverage$617100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie15$302
GSK1$125
Pfizer5$79
Johnson & Johnson3$65
UCB, Inc.1$29
Amgen1$17

How this compares

$617 in reported general payments places this provider in the 70th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$54,115
Medicare patients
24
Services billed
5,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxychloroquine Sulfate40$1,047
Leflunomide15$725
Prednisone35$317
MethotrexateMethotrexate Sodium20$245

Paid to pharmacies, not to this prescriber.

Other rheumatology in Burnsville

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →